Opko Health Inc. (OPK) CEO Purchases $57,900.00 in Stock

Share on StockTwits

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock in a transaction on Wednesday, September 5th. The stock was bought at an average price of $5.79 per share, for a total transaction of $57,900.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $17,769,226.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 30th, Phillip Md Et Al Frost purchased 5,000 shares of Opko Health stock. The stock was bought at an average price of $5.90 per share, for a total transaction of $29,500.00.
  • On Tuesday, August 28th, Phillip Md Et Al Frost purchased 5,000 shares of Opko Health stock. The stock was bought at an average price of $5.80 per share, for a total transaction of $29,000.00.
  • On Friday, August 24th, Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock. The stock was bought at an average price of $5.70 per share, for a total transaction of $85,500.00.
  • On Friday, August 17th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was bought at an average price of $5.54 per share, for a total transaction of $55,400.00.
  • On Monday, August 13th, Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock. The stock was bought at an average price of $5.33 per share, for a total transaction of $79,950.00.
  • On Thursday, August 9th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was bought at an average price of $5.45 per share, for a total transaction of $54,500.00.
  • On Thursday, July 26th, Phillip Md Et Al Frost purchased 90,000 shares of Opko Health stock. The stock was bought at an average price of $5.06 per share, for a total transaction of $455,400.00.
  • On Tuesday, July 24th, Phillip Md Et Al Frost purchased 55,000 shares of Opko Health stock. The stock was bought at an average price of $5.60 per share, for a total transaction of $308,000.00.
  • On Friday, July 20th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was acquired at an average cost of $5.89 per share, with a total value of $58,900.00.
  • On Wednesday, July 18th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.05 per share, with a total value of $60,500.00.

Shares of OPK stock traded down $0.17 during trading hours on Thursday, reaching $5.63. 156,839 shares of the stock were exchanged, compared to its average volume of 3,665,189. Opko Health Inc. has a 12-month low of $2.66 and a 12-month high of $7.24. The company has a current ratio of 1.05, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. The stock has a market cap of $3.31 billion, a PE ratio of -19.76 and a beta of 2.09.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. The firm had revenue of $263.69 million during the quarter, compared to analysts’ expectations of $260.37 million. sell-side analysts forecast that Opko Health Inc. will post -0.23 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of Opko Health by 38.7% during the 2nd quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares during the period. Mackay Shields LLC purchased a new position in shares of Opko Health during the 1st quarter worth about $8,873,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Opko Health by 49.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 2,395,831 shares of the biotechnology company’s stock worth $11,261,000 after purchasing an additional 788,753 shares during the period. Canada Pension Plan Investment Board boosted its stake in shares of Opko Health by 22.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 2,263,400 shares of the biotechnology company’s stock worth $10,638,000 after purchasing an additional 418,200 shares during the period. Finally, IFP Advisors Inc boosted its stake in shares of Opko Health by 2.4% during the 2nd quarter. IFP Advisors Inc now owns 2,179,110 shares of the biotechnology company’s stock worth $10,242,000 after purchasing an additional 50,422 shares during the period. 24.81% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have commented on OPK shares. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating and set a $4.75 price objective for the company in a research note on Wednesday, May 9th. Barrington Research reissued a “buy” rating and issued a $7.00 price objective on shares of Opko Health in a research note on Wednesday, May 9th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 12th. Finally, ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Opko Health presently has an average rating of “Hold” and an average price target of $10.95.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Article: How Do Tariffs Affect Trade Balances?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply